silybin has been researched along with paclitaxel in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
| Choi, JS; Lee, CK | 1 |
| Chang, HR; Chen, PN; Chu, SC; Hsieh, YS; Hung, TW; Lian, JD; Sun, YS; Wu, SW; Yang, SF | 1 |
| Asiaee, F; Hejazi, M; Lai, R; Molavi, O; Narimani, F; Sharifi, S; Shayanfar, A; Tarhriz, V | 1 |
| Akbarzadeh, A; Ebrahimie, E; Khodadadi, K; Pashaei-Asl, F; Pashaei-Asl, R; Pashaiasl, M | 1 |
| Ge, Y; Lou, D; Ping, X; Shi, W; Yu, M; Zhang, Y | 1 |
| Cai, H; Huo, M; Li, L; Wang, H; Yin, T; Zhang, P; Zhang, Y; Zhou, J | 1 |
| Bamezai, RN; Chattopadhyay, S; Iqbal, MA; Khan, A; Prakasam, G; Siddiqui, FA; Siddiqui, S; Sultana, S; Ur Rehman, A | 1 |
9 other study(ies) available for silybin and paclitaxel
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Herb-Drug Interactions; Injections, Intravenous; Male; Metabolic Clearance Rate; Paclitaxel; Rats; Rats, Sprague-Dawley; Silybin; Silymarin | 2010 |
Silibinin inhibits the invasion and migration of renal carcinoma 786-O cells in vitro, inhibits the growth of xenografts in vivo and enhances chemosensitivity to 5-fluorouracil and paclitaxel.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Renal Cell; Cell Line; Cell Line, Tumor; Cell Movement; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Fluorouracil; HEK293 Cells; Humans; Kidney Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred ICR; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Paclitaxel; Silybin; Silymarin; Urokinase-Type Plasminogen Activator; Xenograft Model Antitumor Assays | 2011 |
Silibinin sensitizes chemo-resistant breast cancer cells to chemotherapy.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; MAP Kinase Signaling System; Paclitaxel; Silybin; Silymarin; STAT3 Transcription Factor | 2017 |
Enhancement of anticancer activity by silibinin and paclitaxel combination on the ovarian cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Ovarian Neoplasms; Paclitaxel; Silybin; Silymarin; Tumor Suppressor Proteins | 2018 |
Synergistic apoptotic effects of silibinin in enhancing paclitaxel toxicity in human gastric cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Silybin; Silymarin; Stomach Neoplasms | 2018 |
Co-delivery of silybin and paclitaxel by dextran-based nanoparticles for effective anti-tumor treatment through chemotherapy sensitization and microenvironment modulation.
Topics: Cell Line, Tumor; Dextrans; Humans; Nanoparticles; Neoplasms; Paclitaxel; Prospective Studies; Silybin; Tissue Distribution; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |
Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Databases, Genetic; Datasets as Topic; Deoxyglucose; Drug Synergism; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Metabolome; Paclitaxel; Proto-Oncogene Proteins c-myc; Signal Transduction; Silybin; Survival Analysis; Triple Negative Breast Neoplasms | 2021 |